Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 15/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 15/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PRF1 | P14222 | 1/20 | 0.33 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401375 | 1.00 | HCRTR1 (0.40) | HCRTR1HCRTR2CYP3A4CSNK1DPDE4B | |
| SCHEMBL636421 | 0.92 | NFE2L2 (0.37) | HCRTR1HCRTR2PDE4BACMSDKDM4E | |
| SCHEMBL636251 | 0.89 | HCRTR1 (0.35) | HCRTR1HCRTR2CSNK1DPRF1ACMSD | |
| SCHEMBL10145401 | 0.89 | HCRTR1 (0.35) | HCRTR1HCRTR2CSNK1DPRF1ACMSD | |
| SCHEMBL638021 | 0.89 | HCRTR1 (0.41) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL4404365 | 0.89 | HCRTR1 (0.41) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL4402314 | 0.88 | HCRTR1 (0.37) | HCRTR1HCRTR2CSNK1DPRF1ACMSD | |
| SCHEMBL4402162 | 0.87 | CSNK1D (0.34) | CSNK1DPRF1ACMSDKDM4EPOLB | |
| SCHEMBL637224 | 0.87 | CSNK1D (0.34) | CSNK1DPRF1ACMSDKDM4EPOLB | |
| SCHEMBL636187 | 0.86 | HCRTR1 (0.41) | HCRTR1HCRTR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2283017-B1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-05 | — | — | EP | claimed |
| US-8518955-B2 | Fused pyrimidineone compounds as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | claimed |
| US-20120115886-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2012-05-10 | — | — | US | claimed |
| US-8119647-B2 | Fused pyrimidineone compounds as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-21 | — | — | US | claimed |
| EP-2283017-B1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-8119647-B2 | Fused pyrimidineone compounds as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115886-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | HCRTR1 1984/4885HCRTR2 1487/4885CYP3A4 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.